...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Epirubicin Bladder cancer Intravesical therapy Eur Urol 1990;17:20-22 1607990 © 1990 S. Karger AG, Basel 0302-2838/90...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Tumor necrosis factor Intravesical therapy Bladder carcinoma 1617066 Clinical Paper Eur Urol 1992;22:112-114 V. Servetta* G. Corseliih B...

... to in the content or advertisements. Intravesical therapy Superficial bladder cancer Mitomycin C Bacillus Calmette-Guérin Eur Urol 1991;20:19-25 © 1991 S. Karger AG, Basel 0302 2838/91/0201 0019$2.75/0 Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial...

.... BCG Intravesical therapy Adverse reactions EurUrol 1995;27(suppl l):23-28 1605409 A.P.M. van der Meijden Bosch Medicentrum, Groot Ziekengasthuis, s Hertogenbosch, The Netherlands Practical Approaches to the Prevention and Treatment of Adverse Reactions to BCG Key Words BCG Intravesical therapy...

.... Superficial bladder cancer BCG Immunotherapy Intravesical therapy D.L. Lamm West Virginia University, Morgantown, W. Va., USA Eur Urol 1995;27(suppl l):2-8 BCG in Perspective: 1605405 Advances in the Treatment of Superficial Bladder Cancer Keywords Superficial bladder cancer BCG Immunotherapy...

...José A. Martínez-Piñero; Luis Martínez-Piñero Superficial bladder cancer Urothelial cancer Intravesical therapy BCG immunotherapy Immune response modifiers 11 8 2017 1997 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. BCG Immunotherapy Chemotherapy Intravesical therapy Superficial bladder cancer Since the discovery...

...; treatment is similar to the one of granulomatous prostatitis, with which it may be associated. A nosocomial infection must be excluded or treated. This is a rare complication (0.3%). Carcinoma in situ must be excluded and permanent drainage may be indicated [ 6 ]. BCG Intravesical therapy Side...

...P.-U. Malmström Intravesical therapy of superficial bladder cancer has been in routine use since the introduction of thiotepa in 1961. An empirical approach has been used to optimize this kind of treatment – clinical data are, unfortunately, often lacking. Marker lesion studies indicate that BCG...

... with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997;15:2564–2569. 2. Lamm DL: Long-term results of intravesical therapy for superficial bladder cancer; in Lamm DL (ed): The Urologic Clinics of North America. Philadelphia...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Vascular endothelial growth factor Angiogenesis Bladder cancer Intravesical therapy...

... Immunotherapy Intravesical therapy Transitional cell carcinoma Failure was defined as abnormal cytology or bladder biopsies, or an obvious bladder tumour indicating early tumour recurrence. Progression was defined as the development of muscle-invasive disease and recurrence as a histologically-proven...